Ractigen Therapeutics Initiates First-in-Human Trial of RAG-18 for Duchenne Muscular Dystrophy
核心洞察
Ractigen Therapeutics has dosed the first patient in an investigator-initiated trial of RAG-18, a small activating RNA therapeutic for Duchenne Muscular Dystrophy (搜索) at Peking Union Medical College Hospital.
RAG-18 utilizes RNA activation technology to target the UTRN gene (搜索) and upregulate utrophin protein (搜索) as a functional replacement for missing dystrophin in DMD (搜索) patients.
The therapy has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation in 2024, with preclinical data showing effective mitigation of muscle damage.
Ractigen Therapeutics has achieved a significant milestone in Duchenne Muscular Dystrophy (搜索) (DMD (搜索)) treatment by dosing the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH (搜索)) in Beijing. This marks the first clinical evaluation of a small activating RNA (saRNA) therapeutic specifically designed to address the underlying genetic cause of DMD across all mutation types.
Novel RNA Activation Approach
RAG-18 represents a first-of-its-kind saRNA candidate that utilizes RNA activation (RNAa) technology to target and activate UTRN gene (搜索) expression in muscle cells. The therapy aims to upregulate utrophin protein (搜索), which is structurally and functionally similar to dystrophin and could serve as a functional replacement for the missing dystrophin in DMD (搜索) muscle cells.
"We are excited to begin this clinical trial with RAG-18, a cutting-edge therapeutic approach for treating DMD (搜索)," stated Professor Dai Yi, the distinguished expert in neuromuscular disorders and Deputy Director of the Neurology Department at PUMCH (搜索) who is leading the study. "We anticipate positive clinical results that could open up new, innovative treatment options for patients and significantly improve their quality of life."
Addressing Treatment Limitations
Current disease-modifying therapeutic approaches for DMD (搜索) include antisense oligonucleotides (ASO) mediated exon skipping, gene therapy, and gene editing, with exon skipping being the most common strategy. However, these treatments have significant limitations, as they are mutation-specific and cannot address all forms of the disease.
RAG-18's approach differs fundamentally by targeting utrophin upregulation rather than dystrophin restoration. Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics, emphasized this advantage: "This treatment has the potential to address all genetic mutations related to DMD (搜索), illustrating RNA activation (RNAa) technology as a revolutionary method in clinical practice and offering hope for previously untreatable conditions."
Preclinical Promise and Regulatory Recognition
Preclinical data demonstrate that RAG-18, delivered through subcutaneous injection utilizing Ractigen's proprietary LiCO™ (lipid-conjugated oligonucleotide) technology, has effectively mitigated muscle damage. The therapeutic potential of this approach has been recognized by the U.S. Food and Drug Administration (搜索), which granted RAG-18 both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) in 2024.
Study Objectives and Design
The IIT aims to assess RAG-18's safety and pharmacokinetic profile while exploring its potential to improve muscle function in DMD (搜索) patients. The study represents a crucial step in validating the RNA activation platform technology, which was developed by Dr. Li and his team as a clinically validated approach that utilizes saRNAs to target gene regulatory domains, activating gene expression and restoring therapeutic protein levels.
Disease Background and Unmet Need
Duchenne Muscular Dystrophy (搜索) is a severe genetic disorder caused by mutations in the dystrophin gene (搜索), which leads to the absence or insufficiency of functional dystrophin protein (搜索) essential for muscle fiber stability. Without this protein, muscle cells are easily damaged and cannot repair themselves, resulting in progressive muscle weakness and degeneration. The dystrophin gene, the largest in the human body, contains 79 exons, making comprehensive treatment approaches particularly challenging.
The initiation of this trial represents a significant advancement in DMD (搜索) therapeutics, potentially offering a universal treatment approach that could benefit all patients affected by this devastating condition, regardless of their specific genetic mutation.